Gil-Sun Hong1, Eun Jin Chae2, Jin-Sook Ryu3, Sun Young Chae3, Hyo Sang Lee4, Dok Hyun Yoon5, Cheolwon Suh5. 1. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea. 2. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea. ejinchae@gmail.com. 3. Department of Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea. 4. Department of Nuclear Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, 38, Bangdong-gil, Sacheon-myeon, Gangneung, South Korea. 5. Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea.
Abstract
BACKGROUND: We prospectively evaluated the diagnostic utility of whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery MRI (WB-DWIBS/STIR) for the pretherapeutic staging of indolent lymphoma in 30 patients. METHODS: This prospective study included 30 treatment-naive patients with indolent lymphomas who underwent WB-DWIBS/STIR and conventional imaging workup plus biopsy. The pretherapeutic staging agreement, sensitivity, and specificity of WB-DWIBS/STIR were investigated with reference to the multimodality and multidisciplinary consensus review for nodal and extranodal lesions excluding bone marrow. RESULTS: In the pretherapeutic staging, WB-DWIBS/STIR showed very good agreement (κ = 0.96; confidence interval [CI], 0.88-1.00), high sensitivity (93.4-95.1%), and high specificity (99.0-99.4%) for the whole-body regions. These results were similar to those of 18F-FDG-PET/CT, except for the sensitivity for extranodal lesions. For extranodal lesions, WB-DWIBS/STIR showed higher sensitivity compared to 18F-FDG-PET/CT for the whole-body regions (94.9-96.8% vs. 79.6-86.3%, P = 0.058). CONCLUSION: WB-DWIBS/STIR is an effective modality for the pretherapeutic staging of indolent lymphoma, and it has benefits when evaluating extranodal lesions, compared with 18F-FDG-PET/CT.
BACKGROUND: We prospectively evaluated the diagnostic utility of whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery MRI (WB-DWIBS/STIR) for the pretherapeutic staging of indolent lymphoma in 30 patients. METHODS: This prospective study included 30 treatment-naive patients with indolent lymphomas who underwent WB-DWIBS/STIR and conventional imaging workup plus biopsy. The pretherapeutic staging agreement, sensitivity, and specificity of WB-DWIBS/STIR were investigated with reference to the multimodality and multidisciplinary consensus review for nodal and extranodal lesions excluding bone marrow. RESULTS: In the pretherapeutic staging, WB-DWIBS/STIR showed very good agreement (κ = 0.96; confidence interval [CI], 0.88-1.00), high sensitivity (93.4-95.1%), and high specificity (99.0-99.4%) for the whole-body regions. These results were similar to those of 18F-FDG-PET/CT, except for the sensitivity for extranodal lesions. For extranodal lesions, WB-DWIBS/STIR showed higher sensitivity compared to 18F-FDG-PET/CT for the whole-body regions (94.9-96.8% vs. 79.6-86.3%, P = 0.058). CONCLUSION:WB-DWIBS/STIR is an effective modality for the pretherapeutic staging of indolent lymphoma, and it has benefits when evaluating extranodal lesions, compared with 18F-FDG-PET/CT.
Entities:
Keywords:
Diffusion-weighted imaging with background body signal suppression; Indolent lymphoma; T2-weighted short-tau inversion recovery MRI; Whole-body magnetic resonance imaging
Authors: Marius E Mayerhoefer; Georgios Karanikas; Kurt Kletter; Helmut Prosch; Barbara Kiesewetter; Cathrin Skrabs; Edit Porpaczy; Michael Weber; Katja Pinker-Domenig; Dominik Berzaczy; Martha Hoffmann; Christian Sillaber; Ulrich Jaeger; Leonhard Müllauer; Ingrid Simonitsch-Klupp; Werner Dolak; Alexander Gaiger; Philipp Ubl; Julius Lukas; Markus Raderer Journal: Clin Cancer Res Date: 2014-04-02 Impact factor: 12.531
Authors: Stuart A Taylor; Sue Mallett; Simon Ball; Sandy Beare; Gauraang Bhatnagar; Angshu Bhowmik; Peter Boavida; John Bridgewater; Caroline S Clarke; Marian Duggan; Steve Ellis; Robert Glynne-Jones; Vicky Goh; Ashley M Groves; Ayshea Hameeduddin; Sam M Janes; Edward W Johnston; Dow-Mu Koh; Sara Lock; Anne Miles; Stephen Morris; Alison Morton; Neal Navani; Alfred Oliver; Terry O'Shaughnessy; Anwar R Padhani; David Prezzi; Shonit Punwani; Laura Quinn; Hameed Rafiee; Krystyna Reczko; Andrea G Rockall; Peter Russell; Harbir S Sidhu; Nicola Strickland; Kathryn Tarver; Jonathan Teague; Steve Halligan Journal: Lancet Respir Med Date: 2019-05-09 Impact factor: 30.700
Authors: C Pawlyn; L Fowkes; S Otero; J R Jones; K D Boyd; F E Davies; G J Morgan; D J Collins; B Sharma; A Riddell; M F Kaiser; C Messiou Journal: Leukemia Date: 2015-12-09 Impact factor: 11.528
Authors: Lukas Lambert; Andrea Burgetova; Marek Trneny; Bianka Bircakova; Jan Molinsky; Katerina Benesova; David Zogala; Pavel Michalek Journal: Quant Imaging Med Surg Date: 2022-02